NCT01491672 - Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG

RAD001

Study drug was supplied as 5 mg tablets in blister packs.

Trial Locations (17)

1784

Novartis Investigative Site, Sofia

8500

Novartis Investigative Site, Rio Negro

90033

Memorial Sloan Kettering Cancer Center, New York

100021

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

125284

Novartis Investigative Site, Moscow

188663

Novartis Investigative Site, Leningrad Region

200032

Novartis Investigative Site, Shanghai

249036

Novartis Investigative Site, Obninsk

310003

Novartis Investigative Site, Hangzhou

510060

Novartis Investigative Site, Guangzhou

603001

Novartis Investigative Site, Nizhny Novgorod

T4000

Novartis Investigative Site, San Miguel de Tucumán

88034-000

Novartis Investigative Site, Florianópolis

14784-400

Novartis Investigative Site, Barretos

01246-000

Novartis Investigative Site, São Paulo

01509-900

Novartis Investigative Site, São Paulo